

IN THE CLAIMS:

Please amend the claims as follows:

Claims 1-2 (Cancelled).

Claim 3 (Currently Amended): A recombinant antibody having an activity of recognizing GM1 ganglioside-bound amyloid β -protein and inhibiting the formation of amyloid fibrils, the antibody being IgG or Fab IgG, Fab, Fab', F(ab')₂, scFv, or dscFv, comprising: a heavy chain variable region, and a light chain variable region; wherein the heavy chain variable region comprises complementary complementarity determining regions (CDRs) described in g), h) and i), and the light chain variable region comprises CDRs described in j), k) and l);

- g) CDR 1 consisting of an amino acid sequence of SEQ ID NO. 1;
- h) CDR 2 consisting of an amino acid sequence of SEQ ID NO. 2;
- i) CDR 3 consisting of an amino acid sequence of SEQ ID NO. 3;
- j) CDR 1 consisting of an amino acid sequence of SEQ ID NO. 4;
- k) CDR 2 consisting of an amino acid sequence of SEQ ID NO. 5; and
- l) CDR 3 consisting of an amino acid sequence of SEQ ID NO. 6.

Claim 4 (Previously Presented): The antibody according to claim 3, wherein the heavy chain variable region comprises an amino acid sequence of SEQ ID NO: 7.

Claim 5 (Previously Presented): The antibody according to claim 3, wherein the light chain variable region comprises an amino acid sequence of SEQ ID NO: 8.

Claim 6 (Previously Presented): The antibody according to claim 3, wherein the heavy chain variable region comprises an amino acid sequence of SEQ ID NO: 7; and the light chain variable region comprises an amino acid sequence of SEQ ID NO: 8.

Claim 7 (Previously Presented): The antibody according to claim 3, which is a humanized antibody.

Claims 8-31 (Canceled).